KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 80 filers reported holding KEROS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $673,306 | -20.7% | 21,120 | 0.0% | 0.00% | – |
| Q2 2023 | $848,602 | +21.9% | 21,120 | +29.6% | 0.00% | – |
| Q1 2023 | $696,010 | -11.1% | 16,300 | 0.0% | 0.00% | – |
| Q4 2022 | $782,726 | +39.5% | 16,300 | +9.4% | 0.00% | – |
| Q3 2022 | $561,000 | +35.5% | 14,900 | -0.7% | 0.00% | – |
| Q2 2022 | $414,000 | -37.6% | 15,000 | +23.0% | 0.00% | – |
| Q1 2022 | $663,000 | -7.1% | 12,200 | 0.0% | 0.00% | – |
| Q4 2021 | $714,000 | +19.6% | 12,200 | -19.2% | 0.00% | – |
| Q3 2021 | $597,000 | -6.9% | 15,100 | 0.0% | 0.00% | – |
| Q2 2021 | $641,000 | -23.4% | 15,100 | +11.0% | 0.00% | – |
| Q1 2021 | $837,000 | -18.2% | 13,600 | -6.2% | 0.00% | – |
| Q4 2020 | $1,023,000 | +278.9% | 14,500 | +107.1% | 0.00% | – |
| Q3 2020 | $270,000 | +17.9% | 7,000 | +14.8% | 0.00% | – |
| Q2 2020 | $229,000 | – | 6,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 321,300 | $12,087,000 | 4.99% |
| First Light Asset Management, LLC | 598,213 | $22,505,000 | 2.28% |
| Nantahala Capital Management | 845,692 | $31,815,000 | 2.06% |
| CHI Advisors LLC | 200,229 | $7,533,000 | 2.03% |
| Fairmount Funds Management LLC | 272,498 | $10,251,000 | 1.80% |
| Altium Capital Management LP | 88,000 | $3,311,000 | 1.21% |
| Orbimed Advisors | 1,679,417 | $63,180,000 | 1.17% |
| SPHERA FUNDS MANAGEMENT LTD. | 206,819 | $7,781,000 | 1.08% |
| Parkman Healthcare Partners LLC | 99,927 | $3,759,000 | 1.07% |
| Soleus Capital Management, L.P. | 146,000 | $5,493,000 | 0.75% |